The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Beneficial effects of terlipressin in hepatorenal syndrome: A prospective, randomized placebo‐controlled clinical trial
Abstract
Background and Aim: Hepatorenal syndrome (HRS) occurs in about 18% of cirrhotic patients with ascites and is characterized by intense renal vasoconstriction, low glomerular filtration rate and preserved tubular function and normal renal histology. The aim of the present study was to examine the effects of terlipressin on renal function, systemic hemodynamics and clinical outcome in patients with HRS. Methods: The study was a randomized controlled single‐blind trial. We randomly assigned 24 consecutive patients with HRS to treatment with terlipressin 1 mg i.v. at 12‐h intervals (group A; n = 12) or placebo at 12‐h intervals (group B; n = 12). The end‐point of the study was improvement in renal functions defined as reversal of HRS and survival at 15 days. Results: The two groups were comparable at baseline. After treatment with terlipressin, urine output significantly (P < 0.05) increased progressively in group A (day 4, 960 ± 40 mL/24 h; day 8, 1068 ± 56 mL/24 h) compared with group B (day 4, 451 ± 40 mL/24 h; day 8, 291 ± 45 mL/24 h). Creatinine clearance improved (P < 0.05) in group A (day 4, 20.2 ± 2.1 mL/min; day 8, 35 ± 2.8 mL/min) compared with group B (day 4, 11.3 ± 1.3 mL/min; day 8, 9.3 ± 1.7 mL/min). Serum creatinine decreased in group A but not in group B (day 8, 1.6 ± 0.01 compared with 3.9 ± 0.26, P < 0.05). Mean arterial pressure increased significantly (P < 0.05) in group A. Terlipressin administration was associated with transient self‐limiting side‐effects including crampy abdominal pain in two patients and cardiac arrhythmias in three patients. Five of the 12 patients survived in group A compared with none in group B at day 15 (P < 0.05) and all survivors had reversal of HRS. Conclusion: In patients with HRS, terlipressin significantly improved renal functions and systemic hemodynamics, and showed a trend towards better clinical outcome. The drug merits further evaluation with different dosages and longer schedules.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis†
Arroyo, V, Ginès, P., Gerbes, A. L., Dudley, F. J., Gentilini, P., Laffi, G., Reynolds, T. B., Ring-Larsen, H., & Schölmerich, J. (1996) · Hepatology · doi:10.1002/hep.510230122 · Cited by 1,703
Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites
Ginès, A., Escorsell, A., Ginès, P., Saló, J., Jiménez, W., Inglada, L., Navasa, M., Clària, J., Rimola, A., Arroyo, V., et al. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90031-7 · Cited by 891
Serum kreatininbestimmung ohne enteiweissen
Bartels, H., Böhmer, M., & Heierli, C. (1972) · Clinica Chimica Acta · doi:10.1016/0009-8981(72)90432-9 · Cited by 804
Reversal of Type 1 Hepatorenal Syndrome With the Administration of Midodrine and Octreotide
Angeli, P., Volpin, R., Gerunda, G., Craighero, R., Roner, P., Merenda, R., Amodio, P., Sticca, A., Caregaro, L., Maffei-Faccioli, A., et al. (1999) · Hepatology · doi:10.1002/hep.510290629 · Cited by 564
Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome
Uriz, J., Ginès, P., Cárdenas, A., Sort, P., Jiménez, W., Salmerón, J. M., Bataller, R., Mas, A., Navasa, M., Arroyo, V., et al. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80158-0 · Cited by 399
Guevara, M., Ginès, P., Fernández‐Esparrach, G., et al. (1998) · Hepatology · doi:10.1002/hep.510270107 · Cited by 331
The Oxford Textbook of Clinical Hepatology
Martin, P. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70235-6 · Cited by 187
Cort, J. H., ALBRECHT, I., Nováková, J., Mulder, J. L., & Jošt, K. (1975) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1975.tb00443.x · Cited by 50
Review article: pharmacological treatment of the hepatorenal syndrome in cirrhotic patients
Dagher, Patch, Marley, Moore, & Burroughs (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00740.x · Cited by 30
Terlipressin may influence the outcome of hepatorenal syndrome complicating alcoholic hepatitis.
Jp, C., Lecomte, T., Cellier, C., et al. (1997) · PubMed · Cited by 26
Cited by
Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis
Salerno, F., Gerbes, A., Ginès, P., Wong, F., & Arroyo, V. (2008) · Postgraduate Medical Journal · doi:10.1136/gut.2006.107789 · Cited by 1,081
Ginès, P., & Schrier, R. W. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0809139 · Cited by 837
Sanyal, A. J., Boyer, T., Garcia–Tsao, G., Regenstein, F., Rossaro, L., Appenrodt, B., Blei, A., Gülberg, V., Sigal, S., & Teuber, P. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.014 · Cited by 663
Acute kidney injury in cirrhosis
Garcia-Tsao, G., Parikh, C. R., & Viola, A. (2008) · Hepatology · doi:10.1002/hep.22605 · Cited by 662
Martín–Llahí, M., Pépin, M., Guevara, M., Díaz, F., Torre, A., Monescillo, A., Soriano, G., Terra, C., Fábrega, E., Arroyo, V., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.024 · Cited by 601
Metadata
- Authors
- SOLANKI, P., CHAWLA, A., GARG, R., GUPTA, R., JAIN, M., & SARIN, S. K.
- Venue
- Journal of Gastroenterology and Hepatology
- Publisher
- Wiley
- Published
- 2003-01-24
- Volume
- 18
- Issue
- 2
- Pages
- 152-156
- ISSN
- 0815-9319 (ISSN-L)
- 1440-1746
- OpenAlex
- W2131903288
- Cited by
- 294
- References
- 10
- FWCI
- 9.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Beneficial effects of terlipressin in hepatorenal syndrome: A prospective, randomized placebo‐controlled clinical trial. https://app.cochat.ai/papers/10.1046/j.1440-1746.2003.02934.x
- The paper
- SOLANKI, P., CHAWLA, A., GARG, R., GUPTA, R., JAIN, M., & SARIN, S. K. (2003). Beneficial effects of terlipressin in hepatorenal syndrome: A prospective, randomized placebo‐controlled clinical trial. Journal of Gastroenterology and Hepatology. https://doi.org/10.1046/j.1440-1746.2003.02934.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.